Literature DB >> 17892505

Role of p38-mitogen-activated protein kinase in ischaemic preconditioning in rat heart.

James R Bell1, Philip Eaton, Michael J Shattock.   

Abstract

1. Activation of p38-mitogen-activated protein kinase (MAPK) has been implicated in the signalling cascade leading to protection by ischaemic preconditioning. This, however, is controversial and there is a plethora of conflicting data in the literature. Although many experimental differences may contribute to this, two in particular may be confounding: (i) the failure to account for p38-MAPK activation during aerobic perfusion; and (ii) the use of the anti-oxidant dimethylsulphoxide (DMSO) as the vehicle for the commonly used p38-MAPK inhibitor SB203580. We have investigated the effects of aerobic perfusion, ischaemia and preconditioning on p38-MAPK activation. In addition, we have used water-soluble SB203580 hydrochloride (SB203580.HCl) and DMSO to probe the role of p38-MAPK in preconditioning and ischaemic injury. 2. Activation of p38-MAPK in rat isolated hearts was assessed using a dual phosphospecific antibody during cannulation, aerobic perfusion and index, autolytic and preconditioned ischaemia. The effect of SB203580.HCl (10 mmol/L) in ischaemic preconditioning and ischaemia/reperfusion was tested using recovery of function and tetrazolium (TTC) staining as end-points. 3. Aerobic perfusion induced rapid activation (34% of maximal ischaemia-induced increase; P < 0.05) of p38-MAPK after 2 min that returned to baseline after 30 min. Index, autolytic and preconditioned ischaemia activated p38-MAPK, with index ischaemia peaking after 15 min (520% of basal; P < 0.05) before declining. SB203580.HCl blocked p38-MAPK activity, but did not block ischaemic preconditioning when bracketing the trigger phase and was not protective when given during ischaemia. 4. In the rat isolated heart, activation of p38-MAPK is neither a unique feature of preconditioning nor a prerequisite. Previous studies using SB203580 may have been complicated by failure to account for the activation of p38-MAPK by the protocol itself and the anti-oxidant properties of the most commonly used vehicle DMSO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17892505     DOI: 10.1111/j.1440-1681.2007.04794.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  10 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

2.  SIRT1 modulates MAPK pathways in ischemic-reperfused cardiomyocytes.

Authors:  Matteo Becatti; Niccolò Taddei; Cristina Cecchi; Niccolò Nassi; Paolo Antonio Nassi; Claudia Fiorillo
Journal:  Cell Mol Life Sci       Date:  2012-02-05       Impact factor: 9.261

Review 3.  Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

Authors:  Sabzali Javadov; Sehwan Jang; Bryan Agostini
Journal:  Pharmacol Ther       Date:  2014-06-09       Impact factor: 12.310

4.  Complement-induced activation of MAPKs and Akt during sepsis: role in cardiac dysfunction.

Authors:  Fatemeh Fattahi; Miriam Kalbitz; Elizabeth A Malan; Elizabeth Abe; Lawrence Jajou; Markus S Huber-Lang; Markus Bosmann; Mark W Russell; Firas S Zetoune; Peter A Ward
Journal:  FASEB J       Date:  2017-06-01       Impact factor: 5.191

Review 5.  New Perspectives on Sex Steroid and Mineralocorticoid Receptor Signaling in Cardiac Ischemic Injury.

Authors:  Laura A Bienvenu; James R Bell; Kate L Weeks; Lea M D Delbridge; Morag J Young
Journal:  Front Physiol       Date:  2022-06-29       Impact factor: 4.755

6.  Tumor Necrosis Factor-α: Life and Death of Hepatocytes During Liver Ischemia/Reperfusion Injury.

Authors:  Maureen Shuh; Humberto Bohorquez; George E Loss; Ari J Cohen
Journal:  Ochsner J       Date:  2013

Review 7.  Protein Kinases as Drug Development Targets for Heart Disease Therapy.

Authors:  Naranjan S Dhalla; Alison L Müller
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-05

8.  A cardiopulmonary bypass with deep hypothermic circulatory arrest rat model for the investigation of the systemic inflammation response and induced organ damage.

Authors:  Melanie Engels; Esra Bilgic; Antonio Pinto; Edwin Vasquez; Lena Wollschläger; Holger Steinbrenner; Kristine Kellermann; Payam Akhyari; Artur Lichtenberg; Udo Boeken
Journal:  J Inflamm (Lond)       Date:  2014-08-12       Impact factor: 4.981

9.  Sevoflurane Pre-conditioning Ameliorates Diabetic Myocardial Ischemia/Reperfusion Injury Via Differential Regulation of p38 and ERK.

Authors:  Dina Xie; Jianli Zhao; Rui Guo; Liyuan Jiao; Yanqing Zhang; Wayne Bond Lau; Bernard Lopez; Theodore Christopher; Erhe Gao; Jimin Cao; Xinliang Ma; Yajing Wang
Journal:  Sci Rep       Date:  2020-01-08       Impact factor: 4.379

10.  The differential effects of FTY720 on functional recovery and infarct size following myocardial ischaemia/reperfusion.

Authors:  Derick van Vuuren; Erna Marais; Sonia Genade; Amanda Lochner
Journal:  Cardiovasc J Afr       Date:  2016 Nov/Dec       Impact factor: 1.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.